Home > Insider Trading > Filing (0001246360-13-000270)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
911326	Synageva Biopharma Corp	GEVA	Biological Products, (No Disgnostic Substances) (2836)	561808663

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532475	Alan Mark Goldberg	128 Spring Street, Suite 520 Lexington MA 02421	Svp, Product Development	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-01-02	4,417	$0.95	4,417	No	4	M	Direct
Common Stock	Disposition	2013-01-02	4,417	$47.52	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2013-01-02	4,417	$0.00	4,417	$0.95

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
12,085		2019-07-01	No	4	M	Direct

Footnotes

The stock option exercise and sale of shares of common stock ("Shares") reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 8, 2012.
The reporting person was granted two options on 07/01/2009. These options are combined for reporting purposes herein. The first option was to purchase 3,300 Shares. 25% of such Shares vested and became exercisable on 10/10/2009, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter. The second was an option to purchase 13,202 Shares. 25% of such Shares vested and became exercisable on 07/01/2010, and 1/36 of the remainder of such Shares vest and become exercisable monthly thereafter.
This transaction was executed in multiple trades through a broker-dealer at prices ranging from $47.01 to $47.82 The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.